|
Outcomes following liver SBRT for metastatic pancreatic cancer. |
|
Oluwadamilola Temilade Oladeru |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Carlos Fernandez Del-Castillo |
No Relationships to Disclose |
|
|
Honoraria - Celgene; Lilly; Merrimack |
Consulting or Advisory Role - Celgene; Merrimack |
Research Funding - Abbvie; Bayer; Celgene; Genentech/Roche; Lilly; Millennium |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Emas pharma |
Research Funding - Pfizer (Inst) |
|
|
Stock and Other Ownership Interests - MPM Capital |
Honoraria - Research to Practice; UpToDate |
Consulting or Advisory Role - Gritstone Bio; MPM Capital; Oncorus |
Patents, Royalties, Other Intellectual Property - Johns Hopkins University Press; McGraw Hill Chapter Royalties |
Other Relationship - TCR2 Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |